BHC — Bausch Health Companies Inc. stock price, charts and financials
QT69Bausch Health Companies Inc.Bausch Health Companies Inc. (NYSE: BHC) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -2.95 | Insider Own | 46.63% | Shs Outstand | 373.99M | Perf Week | -3.24% |
| Market Cap | 2.12B | Forward P/E | 1.30 | EPS next Y | 4.37 | Insider Trans | -0.04% | Shs Float | 331.22M | Perf Month | -17.71% |
| Enterprise Value | 21.07B | PEG | 0.00 | EPS next Q | 1.27 | Inst Own | - | Short Float | 2.48% | Perf Quarter | 18.87% |
| Income | -1.10B | P/S | 0.20 | EPS this Y | 255.38% | Inst Trans | - | Short Ratio | 2.33 | Perf Half Y | 12.72% |
| Sales | 10.85B | P/B | - | EPS next Y | -4.60% | ROA | -4.43% | Short Interest | 8.22M | Perf YTD | -18.42% |
| Book/sh | - | P/C | 1.18 | EPS next 5Y | -6.11% | ROE | 88.77% | 52W High | 8.00 -29.12% | Perf Year | -16.98% |
| Cash/sh | - | P/FCF | 1.52 | EPS past 3/5Y | - | ROIC | 13.07% | 52W Low | 4.33 30.95% | Perf 3Y | -34.30% |
| Dividend Est. | - | EV/EBITDA | 10.30 | Sales past 3/5Y | 8.11% 5.04% | Gross Margin | 71.82% | Volatility | 3.32% 4.18% | Perf 5Y | -80.07% |
| Dividend TTM | - | EV/Sales | 1.94 | EPS Y/Y TTM | -2169.23% | Oper. Margin | 25.44% | ATR (14) | 0.28 | Perf 10Y | -81.07% |
| Dividend Ex-Date | Nov 10, 2010 | Quick Ratio | 1.08 | Sales Y/Y TTM | 12.76% | Profit Margin | -10.12% | RSI (14) | 38.99 | Recom | 2.61 |
| Dividend Gr. 3/5Y | -13.82% 20.68% | Current Ratio | 1.44 | EPS Q/Q | 40.00% | SMA20 | -9.35% | Beta | 0.36 | Target Price | 9.83 |
| Payout | 0.00% | Debt/Eq | - | Sales Q/Q | 12.73% | SMA50 | -3.61% | Rel Volume | 0.52 | Prev Close | 5.65 |
| Employees | 20,300 | LT Debt/Eq | 55.61 | Earnings | Oct 28 | SMA200 | -2.89% | Avg Volume | 3.58M | Price | 5.67 |
| IPO Date | Mar 29, 1994 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 28.41% 8.74% | Net Debt/EBITDA | 9.26 | Volume | 1,854,315 | Change | 0.35% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jan-07-26 | Reiterated | Truist Securities | Hold | $7.00 → $8.00 |
| Dec-08-25 | Initiated | Barclays | Equal Weight | $8.00 |
| Feb-06-25 | Downgrade | Jefferies | Buy → Hold | |
| Oct-23-24 | Reiterated | RBC Capital | Sector Perform | $8.50 → $10 |
| Aug-02-24 | Downgrade | Piper Sandler | Neutral → Underweight | |
| Jul-25-24 | Reiterated | Truist Securities | Hold | $7.00 |
| Jul-10-24 | Initiated | Raymond James | Market Perform on Xifaxan risk | $8.00 |
| Apr-29-24 | Reiterated | Piper Sandler | Neutral | $6.00 → $9.00 |
| Apr-23-24 | Reiterated | RBC Capital | Sector Perform | $12 → $11 |
| Apr-11-24 | Reiterated | Jefferies | Buy | $16 |
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 10,853 | 10,266 | 9,625 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 3,058 | 3,013 | 2,782 | — | — | — | — | — | — | |
| Gross Profit | 7,795 | 7,253 | 6,843 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 3,445 | 3,438 | 3,283 | — | — | — | — | — | — | |
| Research and Development | 634 | 629 | 634 | — | — | — | — | — | — | |
| Other Operating Expense | 955 | 1,001 | 1,380 | — | — | — | — | — | — | |
| Operating Income | 2,761 | 2,185 | 1,546 | — | — | — | — | — | — | |
| Interest Expense | 1,607 | 1,604 | 1,388 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1,886 | -214 | 9 | — | — | — | — | — | — | |
| Net Income Before Taxes | -732 | 367 | 167 | — | — | — | — | — | — | |
| Income Taxes | 361 | 247 | 239 | — | — | — | — | — | — | |
| Consolidated Net Income | -1,098 | 157 | -46 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -1,093 | 120 | -72 | — | — | — | — | — | — | |
| Net Income | -1,098 | 157 | -46 | — | — | — | — | — | — | |
| EPS (Recurring) | -2.95 | 0.43 | -0.13 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.95 | 0.43 | -0.13 | — | — | — | — | — | — | |
| EPS (Diluted) | -2.95 | 0.43 | -0.13 | — | — | — | — | — | — | |
| EBITDA | 2,047 | 3,179 | 3,134 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 16.16 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.20 | 0.25 | 0.31 | — | — | — | — | — | — | |
| Gross Margin | 71.82 | 70.65 | 71.10 | — | — | — | — | — | — | |
| Operating Margin | 25.44 | 21.28 | 16.06 | — | — | — | — | — | — | |
| Net Margin | -10.12 | 1.53 | -0.48 | — | — | — | — | — | — | |
| Shares Outstanding | 375 | 371 | 368 | — | — | — | — | — | — | |
| Market Capitalization | 2,126 | 2,578 | 2,966 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Lenar Aimee J. | President, US Pharma | Aug 19 '26 | Sale | 7.03 | 36,827 | 258,894 | 334,853 | Aug 20 |
| Lee Frank D. | Director | May 19 '26 | Sale | 5.43 | 24,456 | 132,796 | 49,339 | May 20 |
| Carson Seana | EVP, General Counsel | Mar 03 '26 | Sale | 5.77 | 4,420 | 25,503 | 616,761 | Mar 03 |
| Carson Seana | EVP, General Counsel | Mar 02 '26 | Sale | 5.78 | 6,856 | 39,628 | 776,076 | Mar 03 |
| Carson Seana | EVP, General Counsel | Feb 27 '26 | Sale | 5.95 | 8,388 | 49,909 | 809,258 | Feb 27 |
| PAULSON & CO. INC. | 10% Owner | Nov 25 '25 | Buy | 6.25 | 2,500,000 | 15,625,000 | 73,255,869 | Nov 28 |
| Carson Seana | EVP, General Counsel | Sep 08 '25 | Sale | 7.31 | 13,370 | 97,735 | 499,585 | Sep 08 |
| Lee Frank D. | Director | Aug 21 '25 | Sale | 7.66 | 15,912 | 121,886 | 73,795 | Aug 22 |
| Paulson John | Director | Aug 14 '25 | Buy | 9.00 | 34,721,118 | 312,490,062 | 70,755,869 | Aug 14 |
| Paulson John | Director | Aug 13 '25 | Buy | 7.06 | 86,409 | 610,048 | 36,034,751 | Aug 13 |
| Paulson John | Director | Aug 12 '25 | Buy | 6.88 | 1,156,640 | 7,957,683 | 35,948,342 | Aug 13 |
| Paulson John | Director | Aug 11 '25 | Buy | 6.35 | 2,000,000 | 12,700,000 | 34,791,702 | Aug 13 |
| Paulson John | Director | Jun 13 '25 | Buy | 5.94 | 3,564,059 | 21,170,510 | 32,791,702 | Jun 17 |
| Paulson John | Director | Jun 12 '25 | Buy | 5.47 | 1,005,376 | 5,499,407 | 29,227,643 | Jun 12 |
| Paulson John | Director | Jun 11 '25 | Buy | 5.24 | 1,029,098 | 5,392,474 | 28,222,267 | Jun 12 |